In English | En español
Questions About Cancer? 1-800-4-CANCER

NCI Drug Dictionary


Haelan 951  
(Other name for: fermented soybean protein beverage)

Haemophilus influenzae b vaccine  
A vaccine against serotype b of the Gram-negative bacterium H. influenzae (Hib). Hib vaccines contain polysaccharide-protein conjugate antigens that produce greater host immune responses than first-generation purified polysaccharide vaccine. These vaccines may differ with regard to use of protein carriers, polysaccharides, diluents, and preservatives. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hafnium oxide-containing nanoparticles NBTXR3  
A suspension of nanoparticles containing inert inorganic hafnium oxide (HfO2) crystals with potential antineoplastic activity. Upon injection of NBTXR3 into the tumor, the hafnium oxide-containing nanoparticles accumulate in the tumor cells. Subsequent application of radiation beams to the tumor tissue causes HfO2 particles to emit huge amounts of electrons. This results in the formation of free radicals within the tumor cells, which in turn causes targeted destruction of the cancer cells. Compared to standard radiotherapy, because of the inert nature of NBTXR3, this agent emits electrons only during its exposure to radiation which improves radiotherapy efficiency. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Haldol  
(Other name for: haloperidol)

Halodrin  
(Other name for: fluoxymesterone)

halofuginone hydrobromide  
The hydrobromide salt of halofuginone, a semisynthetic quinazolinone alkaloid anticoccidial derived from the plant Dichroa febrifuga, with antifibrotic and potential antineoplastic activities. Halofuginone specifically inhibits collagen type I gene expression and matrix metalloproteinase 2 (MMP-2) gene expression, which may result in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to be due to halofuginone-mediated inhibition of the collagen type I and MMP-2 promoters. Collagen type I and MMP-2 play important roles in fibro-proliferative diseases. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

haloperidol  
A phenylbutylpiperadine derivative with antipsychotic, neuroleptic, and antiemetic activities. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. Antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Halotestin  
(Other name for: fluoxymesterone)

Havrix  
(Other name for: hepatitis A vaccine)

HDAC inhibitor 4SC-202  
An orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity. HDAC inhibitor 4SC-202 selectively binds to and inhibits class I HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, the selective transcription of tumor suppressor genes, and the tumor suppressor protein-mediated inhibition of tumor cell division and eventually the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HDAC inhibitor CG200745  
A histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CG200745 inhibits the catalytic activity of HDAC, resulting in an accumulation of highly acetylated chromatin histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. In particular, this agent enhances the histone acetylation of the tumor suppressor gene p53. This results in an accumulation of p53, p53-dependent transactivation and apoptosis in tumor cells. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HDAC inhibitor CHR-2845  
A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CHR-2845 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HDAC inhibitor CHR-3996  
An orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor CHR-3996 inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes; these events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. This agent may upregulate HSP70 and downregulate anti-apoptotic Bcl-2 proteins more substantially than some first-generation HDAC inhibitors. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HDAC inhibitor PCI-24781  
A broad-spectrum phenyl hydroxamic acid inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor PCI-24781 inhibits several isoforms of HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, this agent has been shown to inhibit homologous recombination (HR) activity by inhibiting the expression of RAD51. RAD51, a homologue of bacterial RecA, assists in the repair of DNA double-strand breaks (DSBs). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HDAC inhibitor SHP-141  
A topical formulation containing the histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Upon cutaneous administration, SHP-141 selectively binds to and inhibits HDAC, resulting in an accumulation of highly acetylated histones in the skin (dermis and epidermis), the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. These events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins. Topical administration of SHP-141 allows for high concentrations of this agent locally while minimizing systemic toxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HDAC/EGFR/Her2 inhibitor CUDC-101  
A multi-targeted, small-molecule inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human epidermal growth factor receptor 2 tyrosine kinase (HER2/neu or ErbB2) with potential antineoplastic activity. HDAC/EGFR/HER2 inhibitor CUDC-101 inhibits the activity of these three enzymes but the exact mechanism of action is presently unknown. This agent may help overcome resistance to inhibition of EGFR and Her2 through a simultaneous, synergistic inhibition of EGFR, Her2, and HDAC. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HDAC6 inhibitor ACY-1215  
An orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. ACY-1215 selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. This leads to an accumulation of unfolded and misfolded ubiquitinated proteins and may eventually induce cancer cell apoptosis, and inhibition of cancer cell growth. HDAC6, a class II HDAC deacetylase located in the cytoplasm, appears to play a key role in the formation and activation of the aggresomes needed for degradation of misfolded proteins. Compared to non-selective HDAC inhibitor, ACY-1215 is able to reduce the toxic effects on normal, healthy cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HDM2 antagonist JNJ-26854165  
An orally bioavailable, small-molecule HDM2 antagonist with potential antineoplastic activity. HDM2 antagonist JNJ-26854165 inhibits the binding of the HDM2–p53 complex to the proteasome, blocking the degradation of p53; p53 signaling and p53-mediated induction of tumor cell apoptosis may thus be restored. In addition to p53, degradation of other HDM2 client proteins may be inhibited. HDM2 (human homolog of double minute 2), a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, this oncoprotein has been implicated in cancer cell proliferation and survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

heat-treated varicella-zoster virus vaccine V212  
A heat-treated varicella-zoster virus (VZV) vaccine with potential immunomodulating activity. Upon vaccination with heat-treated varicella-zoster virus vaccine V212, this vaccine may activate the immune system to generate specific anti-VZV antibodies and an active immunity against VZV infection. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hectorol  
(Other name for: doxercalciferol)

Hedgehog inhibitor PF-04449913  
An orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic activity. Hedgehog inhibitor PF-04449913 appears to inhibit Hh pathway signaling. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hematide  
(Other name for: synthetic peptide-based erythropoiesis stimulating agent)

hematoporphyrin derivative  
A complex mixture of monomeric and aggregated porphyrins with photosensitizing activity. Upon systemic administration, hematoporphyrin derivatives accumulate in tumor cells and, once activated by red laser light (630 nm), in the presence of oxygen, produce singlet oxygen and other reactive oxygen radicals, resulting in local radical-mediated tumor cell death. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hemiasterlin analog E7974  
An analog of the sponge-derived anti-microtubule tripeptide hemiasterlin with antimitotic and potential antineoplastic activities. Hemiasterlin analog E7974 binds to the Vinca domain on tubulin, resulting in inhibition of tubulin polymerization and microtubule assembly; depolymerization of exsiting microtubules; inhibition of mitosis; and inhibition of cellular proliferation. This agent may have more affinity for the beta-3 tubulin isotype. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

henatinib maleate  
The maleate salt form of henatinib, an orally bioavalable, multitargeted tyrosine kinase inhibitor with potential antitumor and antiangiogenic activities. Henatinib inhibits vascular endothelial growth factor receptor type 2 (VEGFR2), a tyrosine kinase receptor upregulated in many tumor cells that plays a key role in angiogenesis. This may result in an inhibition of angiogenesis and eventually tumor cell proliferation. Henatinib, structurally similar to sunitinib, also inhibits, though to a lesser extent, mast/stem cell growth factor receptor (c-Kit) and, platelet-derived growth factor receptor (PDGFR) alpha and beta. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

heparan sulfate glycosaminoglycan mimetic M402  
A low molecular weight heparin derivative and heparan sulfate proteoglycan (HSPG) mimetic with no or minimal anticoagulant activity and potential antineoplastic activities. Upon administration, M402 mimics HSPGs by binding to and inhibiting various heparin-binding growth factors, chemokines, and cytokines such as VEGF, HGF, FGF2, SDF-1a, heparanase and P-selectin all of which are essential for tumor angiogenesis and metastasis to occur. This inhibits heparin binding growth factor-mediated signaling and disrupts tumor-stromal interactions eventually leading to an inhibition of angiogenesis and tumor cell progression. In addition, M402 may enhance the cytotoxic effect of other chemotherapeutic agents. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

heparin  
A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hepatitis A vaccine  
An inactivated virus vaccine that provides active immunization against hepatitis A virus (HAV). Immunization with hepatitis A vaccine induces the formation of anti-HAV antibodies which provide protection against hepatitis A infection. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hepatitis B vaccine (recombinant)  
A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle. Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hepsera  
(Other name for: adefovir dipivoxil)

hepsulfam  
A bisulfamic ester which is similar in structure to busulfan and belongs to the family of drugs known as alkylsulfonate alkylating agents. Hepsulfam forms covalent linkages with nucleophilic centers in DNA, resulting in depurination, base miscoding, strand scission, DNA-DNA and DNA-protein cross-linking, and cytotoxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine  
A vaccine comprised of HER-2-neu and carcinoembryonic antigen synthetic (CEA) peptides, combined with the adjuvants granulocyte-macrophage colony stimulating factor (GM-CSF), and Montanide ISA-51 with potential antineoplastic activity. HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine may stimulate a cytotoxic T-cell response against HER-2-neu- and CEA-expressing tumor cells. The GM-CSF adjuvant stimulates the proliferation of monocytes and monocyte differentiation into macrophages and dendritic cells, immunohematopoietic elements with important antitumoral functions. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HER-2/neu intracellular domain protein  
The cytoplasmic domain or intracellular domain (ICD) of the HER2/neu protein that exhibits tyrosine kinase activity. Based on sensitization theory, co-administration of trastuzumab (anti-HER-2/neu monoclonal antibody) and HER-2/neu intracellular domain protein may result in the potentiation of a HER2/neu-specific cytotoxic T lymphocyte (CTL) response against tumor cells overexpressing the HER2/neu protein. HER-2/neu protein, a glycoprotein cell surface receptor that is composed of an extracellular domain (ECD), a transmembrane domain, and an ICD, is overexpressed by many adenocarcinomas including breast adenocarcinoma. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HER-2/neu peptide vaccine  
A cancer vaccine comprised of peptides derived from the extracellular domain of the tumor-associated antigen Her-2/neu with potential antineoplastic activity. HER-2/neu peptide vaccine may induce antibodies with anti-tumor activity and may also elicit a specific CD8 T-cell response against specific tumor cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HER2 ECD+TM virus-like replicon particles vaccine AVX901  
A cancer vaccine based on virus-like replicon particles (VRP) packaged with an alphaviral vector encoding the extracellular domain (ECD) and transmembrane (TM) regions of the human epidermal growth factor receptor 2 (EGFR2, NEU or HER2), with potential antineoplastic activity. After immunization with HER2 ECD+TM virus-like replicon particles vaccine AVX901, the VRPs infect cells and express HER2 ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. The alphaviral replicon of this vaccine is an attenuated strain of the Venezuelan equine encephalitis virus (VEEV) in which 3 of the 7 viral genes were substituted with a truncated HER2 gene to create a self-amplifying replicon RNA. HER2, a tyrosine kinase involved in several cell growth signaling pathways, is dysregulated or overexpressed in a wide variety of cancer cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HER2-targeted liposomal doxorubicin hydrochloride MM-302  
An antibody-targeted lipidic nano-carrier containing the antineoplastic anthracycline antibiotic doxorubicin encapsulated within liposomes, and conjugated to a monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), with potential antitumor activity. Upon administration of HER2-targeted liposomal doxorubicin hydrochloride MM-302, the immunoliposome allows for specific delivery of doxorubicin to tumors overexpressing the HER2 receptor. Once inside the HER2-expressing tumor cells, doxorubicin intercalates into DNA and interferes with topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis. Compared to doxorubicin alone or liposomal doxorubicin, targeted liposomal delivery of doxorubicin improves efficacy while lowering the toxicity profile. HER2, a tyrosine kinase receptor, is overexpressed in many cancer cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HER2Bi-armed activated T cells  
Activated T cells (ATC) that have been coated with bispecific antibodies (BiAb), with potential antineoplastic and immunomodulating activities. In vitro, T cells are activated through exposure to the anti-CD3 murine monoclonal antibody OKT3 and interleukin 2 for 14 days and then armed with anti-CD3 × anti-Her2 bispecific antibody (Her2Bi). Upon administration, HER2Bi-armed activated T cells attach to CD3-expressing T cells and HER2/neu-expressing tumor cells, selectively cross-linking T cells and tumor cells; this may result in the recruitment and activation of cytotoxic T lymphocytes (CTLs), CTL perforin-mediated tumor cell cytolysis, and the secretion of antitumor cytokines and chemokines. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

herba scutellaria barbata  
A Chinese herb isolated from the plant Scutellaria barbata D. Don (Lamiaceae) with potential antineoplastic activity. Containing the antioxidant flavone scutellarin, herba Scutellaria barbata has been shown to induce apoptosis of ovarian and breast tumor cells in vitro. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

herbal polysaccharide saliva substitute  
A plant-based, proprietary formulation of saliva substitute with potential anti-xerostomia activity. Extracted from the plant called yerba santa (holy herb), herbal polysaccharide saliva substitute contains plant mucins, which is nearly identical to that of human mucous membranes. Upon direct application using the polysaccharide-containing spray, a protective film of moisture is deposited over the mucous membranes of the mouth and throat. The xylitol in this preparation protects against the formation of harmful oral flora and thus helps to prevent cavities. Moreover, this agent has shown a demineralization effect on dentin. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Herceptin  
(Other name for: trastuzumab)

Herplex  
(Other name for: idoxuridine)

Hexa-Betalin  
(Other name for: pyridoxine hydrochloride)

hexadecyloxypropyl-cidofovir  
An alkoxyalkyl ester prodrug containing the synthetic, acyclic nucleoside monophosphate analog cidofovir linked, through its phosphonate group, to a lipid, 3-hexadecyloxy-1-propanol, with antiviral activity against double-stranded DNA viruses. Upon oral administration, hexadecyloxypropyl-cidofovir crosses the intestinal wall and penetrates target viral-infected cells before being cleaved to the free antiviral agent cidofovir. In turn, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses. Compared to cidofovir, which is given intravenously, hexadecyloxypropyl-cidofovir shows better oral bioavailability, less toxicity and enhanced cellular penetration. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hexadrol  
(Other name for: dexamethasone)

Hexalen  
(Other name for: altretamine)

hexamethylene bisacetamide  
A hybrid polar-planar compound with potential antineoplastic activity that induces terminal differentiation, inhibits cell growth, and causes apoptosis in several tumor cell lines. Its precise mechanism of action is unknown. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hexamethylmelamine  
(Other name for: altretamine)

hexaminolevulinate  
The hexyl ester of 5-aminolevulinic acid (ALA) with photodynamic properties. As a precursor of photoactive porphorins, hexaminolevulinate induces the endogenous production of the photosensitizer protoporphyrin IX (PPIX) which accumulates selectively in tumor tissue. When exposed to specific wavelengths of light, PPIX is activated and, depending on the wavelength and/or intensity of light, either fluoresces, thereby allowing tumor imaging, or induces tumor cell apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hextend  
(Other name for: hydroxyethyl starch)

Hexvix  
(Other name for: hexaminolevulinate)

HexvixR  
(Other name for: hexaminolevulinate)

HibTITER  
(Other name for: Haemophilus influenzae b vaccine)

HIF-1alpha inhibitor PX-478  
An orally active small molecule with potential antineoplastic activity. Although its mechanism of action has yet to be fully elucidated, HIF1-alpha inhibitor PX-478 appears to inhibit hypoxia-inducible factor 1-alpha (HIF1A) expression, which may result in decreased expression of HIF1A downstream target genes important to tumor growth and survival, a reduction in tumor cell proliferation, and the induction of tumor cell apoptosis. The inhibitory effect of this agent is independent of the tumor suppressor genes VHL and p53 and may be related to derangements in glucose uptake and metabolism due to inhibition of glucose transporter-1 (Glut-1). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

high-selenium baker's yeast  
A baker’s yeast (Saccharomyces cerevisiae) containing high levels of the trace element selenium (Se) with potential chemopreventive, immunomodulating and antioxidant activities. Selenium is introduced into yeast during fermentation and incorporated into selenocompounds, such as selenomethionine and glutamyl SE methylselenocysteine. Selenium functions as a cofactor for antioxidant enzymes such as glutathione peroxidases and thioredoxin reductase. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

high-selenium Brassica juncea  
A formulation of the mustard plant Brassica juncea grown in a medium that has been enriched with the trace element selenium with potential chemopreventive and chemopotentiating activities. Brassica juncea hyperaccumulates trace elements in soil. Selenium amino acid species found in selenized Brassica juncea include methylselenomethionine (MeSeMet) and methylselenocysteine (MeSeCys); both may be incorporated into selenoproteins in vivo. Selenium functions as a cofactor for antioxidant enzymes such as glutathione peroxidases and thioredoxin reductase, which protect cells from the free radical damage. In addition, in vitro MeSeCys has been shown to potentiate the antitumor effects of the irinotecan metabolite SN-38, by inducing phosphorylation of checkpoint kinase 2 (chk2) at threonine 68, which results in poly(ADP-ribose) polymerase cleavage, caspase 3 activation, and DNA fragmentation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hiltonol  
(Other name for: poly ICLC)

histrelin acetate  
The acetate salt form of histrelin, a long-acting, synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) with potential anti-tumor activity. Upon administration, histrelin binds to and activates GnRH receptors; prolonged administration results in pituitary GnRH receptor desensitization and inhibition of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion, leading to a significant decline in testosterone production in males and may inhibit androgen receptor-positive tumor progression; in females, prolonged administration results in decreased estradiol production. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hivid  
(Other name for: zalcitabine)

HLA-A*0201-restricted TRP2-gp100-EphA2-HER2 multipeptide vaccine  
A cancer vaccine containing four HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigens (TAAs) tyrosinase-related protein 2 (TRP2), glycoprotein 100 (gp100), Ephrin receptor A2 (EphA2) and human epidermal growth factor receptor 2 (HER2). Upon administration, HLA-A*0201-restricted TRp2-gp100-EphA2-HER2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against TRP2-gp100-EphA2-HER2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine  
A cancer vaccine containing three HLA-A*2402-restricted peptide epitopes with potential immunostimulatory, antiangiogenic, and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigen (TAA) URLC (up-regulated in lung cancer 10) and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells and the tumor microvasculature expressing VEGFR 1 and 2 peptides; this may result in tumor cell lysis, the inhibition of tumor angiogenesis, and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*0201-restricted VEGFR1 peptide vaccine  
A cancer vaccine containing an HLA-A*0201-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide (sequence: TLFWLLLTL) with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*0201-restricted VEGFR1-derived peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR1, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine  
A cancer vaccine containing two HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from: vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2402-restricted CDCA1-A24-56 peptide vaccine  
A cancer vaccine containing the HLA-A*2402-restricted peptide epitope derived from cell division associated gene 1 (CDCA1), with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*2402-restricted CDCA1-A24-56 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against CDCA1-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2402-restricted CDCA1-KIF20A multipeptide vaccine  
A cancer vaccine containing two HLA-A*2402-restricted peptide epitopes derived from cancer-testis antigens with potential immunostimulatory and antitumor activities. The peptide epitopes are derived from cell division associated 1 (CDCA1) and kinesin-like family member 20A (KIF20A). Upon administration, HLA-A*2402-restricted CDCA1-KIF20A multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against CDCA1- and KIF20A-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2402-restricted KOC1-TTK-CO16-DEPDC1-MPHOSPH1 multipeptide vaccine  
A cancer vaccine containing five HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from IGF II mRNA binding protein 3 (KOC1); TTK protein kinase (TTK); URLC10 (up-regulated lung cancer 10); DEP domain containing 1 (DEPDC1); and M phase phosphoprotein 1 (MPHOSPH1). Upon administration, HLA-A*2404-restricted KOC1-TTK-CO16-DEPDC1-MPHOSPH1 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing KOC1, TTK, CO16, DEPDC1 and MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2402-restricted multipeptide vaccine S-488410  
A cancer vaccine composed of HLA-*2402-restricted epitopic peptides derived from three cancer/testis (CT) antigens, with potential antineoplastic activity. Upon subcutaneous administration, HLA-A*2402-restricted multipeptide vaccine S-488410 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these CT antigens. CT antigens, normally expressed only in germ cells of the testis, are overexpressed in a wide variety of human cancers. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2402-restricted URLC10 peptides vaccine  
A cancer vaccine containing HLA-A*2402-restricted epitope peptides URLC10 (up-regulated lung cancer 10) with potential immunostimulatory and antineoplastic activities. Upon administration, HLA-A*2402-restricted URLC10 peptides vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells. URLC10, a tumor associated antigen, is often overexpressed in lung, esophageal and gastric cancers. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2402-restricted URLC10-CDCA1-KIF20A multipeptide vaccine  
A cancer vaccine containing three HLA-A*2402-restricted peptide epitopes derived from cancer-testis antigens with potential immunostimulatory and antitumor activities. The peptide epitopes are derived from up-regulated lung cancer 10 (URLC10); cell division cycle associated 1 (CDCA1); and kinesin-like family member 20A (KIF20A). Upon administration, HLA-A*2402-restricted URLC10-CDCA1-KIF20A multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URL10-, CDCA1-, and KIF20A-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2402-restricted URLC10-CDCA1-VEGFR1-VEGFR2 multipeptide vaccine  
A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. The peptide epitopes are derived from URLC10 (up-regulated lung cancer 10); CDCA1 (cell division associated 1); and vascular endothelial growth factor receptors (VEGFRs) 1 and 2. Upon administration, HLA-A*2402-restricted URLC10-CDCA1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URL10-, CDCA1-, VEGFR1- and VEGFR2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2402-restricted URLC10-KOC1-VEGFR1-VEGFR2 multipeptide vaccine  
A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from URLC10 (up-regulated lung cancer 10 or CO16); KOC1 (IGF II mRNA Binding Protein 3); and vascular endothelial growth factor receptors (VEGFRs) 1 and 2. Upon administration, this multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URL10-, KOC1-, VEGFR1- and VEGFR2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2402-restricted URLC10-TTK-KOC1 multipeptide vaccine  
A cancer vaccine containing three HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from URLC10 (up-regulated lung cancer 10); TTK (TTK protein kinase); and KOC1 (IGF II mRNA Binding Protein 3). Upon administration, URLC10-TTK-KOC1 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK and KOC1 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2402-restricted URLC10-TTK-VEGFR1-VEGFR2 multipeptide vaccine  
A cancer vacine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from: URLC10 (up-regulated lung cancer 10), TTK (TTK protein kinase), and VEGFRs (vascular endothelial growth factor receptors) 1 and 2. Upon administration, URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK, VEGFR 1 and 2 peptides, resulting in cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2402-restricted VEGFR1 peptide vaccine  
A cancer vaccine containing the HLA-A*2402-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide epitope with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*2402-restricted VEGFR1 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR 1 peptide, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine  
A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from ring finger protein 43 (RNF43); translocase of outer mitochondrial membrane 34 (TOMM34); and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing RNF43, TOMM34, and VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine  
A peptide vaccine comprised of synthetic HLA-A1, -A2 and -B35 restricted survivin epitopes combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. Upon administration, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine may stimulate a cytotoxic T cell response against tumor cells that overexpress survivin, resulting in tumor cell lysis. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine  
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A1-binding melanoma-associated antigen peptides MAGE-1 and MAGE-3 with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against MAGE1- and MAGE-3-expressing cancer cells, resulting in tumor cell lysis. HLA-A1 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A1 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine  
A peptide vaccine comprised of synthetic HLA-A2- and HLA-A3-binding peptides, derived from amino acid sequences of fibroblast growth factor-5 (FGF-5), combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. HLA-A2, A3-restricted FGF-5 peptides contain motifs recognized by the MHC class I molecules HLA-A2 and HLA-A3 and may stimulate a cytotoxic T-cell response against tumor cells that overexpress FGF-5. Montanide ISA-51 (also known as incomplete Freund's adjuvant or IFA), a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine  
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted melanoma-associated antigen peptides tyrosinase (TYR), MART-1(melanoma antigen recognized by T-cells) and melanoma antigen glycoprotein 100 (gp100), with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against Tyr-, MART-1 and gp100-expressing cancer cells, resulting in tumor cell lysis. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HLA-A2-restricted synthetic glioma antigen peptides vaccine  
A synthetic peptide cancer vaccine consisting of HLA-A2-restricted peptides derived from glioma-associated antigens (GAA) with potential immunostimulating and antineoplastic activities. Upon administration, HLA-A2-restricted synthetic glioma antigen peptides vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the corresponding GAAs, resulting in glioma tumor cell lysis. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hodgkin's antigens-GM-CSF-expressing cell vaccine  
An allogeneic vaccine consisting of Hodgkin lymphoma cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, Hodgkin antigens-GM-CSF-expressing cell vaccine may stimulate a cytotoxic T-lymphocyte (CTL) immune response against Hodgkin lymphoma-associated antigens, which may result in the lysis of tumor cells expressing these antigens. In addition, transfected Hodgkin lymphopma cells secrete GM-CSF, which may potentiate the CTL response against Hodgkin lymphoma-associated antigens. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

honey  
A sweet and viscous fluid produced by honey bees from flower nectar and other plant fluids. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

honey-containing mouthwash  
A mouthwash containing honey with potential antimucositis activity. Upon rinsing with this mouthwash, honey modulates the production of pro-inflammatory cytokines which may kill bacteria thus potentially preventing inflammation of the mucosal membranes and may decrease chemotherapy- and/or radiation-induced oral mucositis. In addition, honey may have a protective and healing effect on the oral mucosa. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

host dendritic cell vaccine-001 MSSM/BIIR  
A dendritic cell (DC) vaccine containing ex vivo expanded autologous DCs obtained from a patient with leukemia with potential immunostimulating activity. Upon reintroduction into the host, the host dendritic cell vaccine-001 MSSM/BIIR may stimulate the immune system to mount a leukemia-specific cytotoxic T lymphocyte (CTL) response. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HPPH  
A lipophilic, second-generation, chlorin-based photosensitizer. Upon intravenous administration, HPPH selectively accumulates in the cytoplasm of cancer or pre-cancerous cells. When laser light is applied, a photodynamic reaction between HPPH and oxygen occurs, resulting in the production of cytotoxic free radicals and singlet oxygen and free radical-mediated cell death. Compared to the first-generation photosensitizer porfimer sodium, HPPH shows improved pharmacokinetic properties and causes only mild skin photosensitivity which declines rapidly within a few days after administration. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HPV 16 E6 peptides vaccine/candida albicans extract  
A human papillomavirus (HPV) type 16 vaccine containing four E6 peptides in combination with the extract of Candida albicans, with potential immunomodulating activity. Upon administration of HPV-16 E6 peptides vaccine/Candida albicans extract, the four HPV-16 E6 peptides and the candida albicans may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against cells expressing the E6 oncoprotein, resulting in tumor cell lysis. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions. Candida albicans allergenic extract may be used as a recall antigen to stimulate the immune system against HPV. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HPV 16 E7:86-93 peptide vaccine  
A synthetic peptide vaccine consisting of amino acids 86 through 93 (TLGIVCPI) of the viral oncoprotein human papillomavirus (HPV) 16 E7. Vaccination with HPV-16 E7:86-93 peptide, which binds to HLA-A* 0201 molecule, may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 E7. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HPV DNA plasmids therapeutic vaccine VGX-3100  
A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV DNA plasmids therapeutic vaccine VGX-3100 expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HPV E1/E2 interaction inhibitor gel AP611074  
A topical gel composed of a human papillomavirus (HPV) E1/E2 protein:protein interaction (PPI) inhibitor with potential antiviral activity. Upon topical application of AP611074, this agent prevents binding of the HPV viral proteins E1 to E2, thereby preventing viral DNA replication and growth of HPV. This inhibits viral proliferation and may prevent the formation of anogenital warts caused by HPV. The HPV proteins E1 and E2 are essential for HPV viral replication. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HPV E6/E7 DNA vaccine GX-188E  
A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV types 16 and 18 are the most common HPV types involved in cervical carcinogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HPV L1 VLP vaccine V504  
A vaccine formulation consisting of several types of human papillomavirus (HPV)-derived noninfectious virus-like particles (VLPs) with potential immunoprophylactic activity. Upon administration, HPV L1 VLP vaccine V504 may generate humoral immunity against various HPV L1 major capsid proteins, thereby preventing cervical infection upon exposure to the associated HPV types. VLPs are composed of self-assembling L1 major capsid proteins or functional L1 major capsid protein derivatives. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hsp27 antisense oligonucleotide OGX-427  
A second-generation antisense oligonucleotide targeting heat shock protein 27 (Hsp27) with potential antitumor and chemosensitizing activities. Hsp27 antisense oligonucleotide OGX-427 suppresses tumor cell expression of Hsp27, which may induce tumor cell apoptosis and enhance tumor cell sensitivity to cytotoxic agents. Hsp27, a chaperone belonging to the small heat shock protein (sHsp) group of proteins, is a cytoprotective protein that supports cell survival under conditions of stress; it has been found to be over-expressed in a variety of human cancers. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hsp90 antagonist KW-2478  
An agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 antagonist KW-2478 appears to inhibit Hsp90, resulting in impaired signal transduction, inhibition of cell proliferation, and the induction of apoptosis in tumor cells. HSP90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hsp90 inhibitor AB-010  
An orally bioavailable nanoparticle albumin-bound inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AB-010 selectively binds to Hsp90, inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This agent may inhibit the growth of a wide variety of cancer cell types; the incorporation of albumin into its formulation may facilitate its endothelial transcytosis through the gp60-regulated albumin transport pathway. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding and degradation of many oncogenic signaling proteins. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hsp90 inhibitor AT13387  
A synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AT13387 selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hsp90 inhibitor AUY922  
A derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Hsp90 inhibitor AUY922 has been shown to bind with high affinity to and inhibit Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines. Hsp90, a 90 kDa molecular chaperone, plays a key role in the conformational maturation, stability and function of other substrate or "client" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors. Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hsp90 inhibitor BIIB028  
A small-molecule inhibitor of heat shock protein (Hsp) 90 with potential antineoplastic activity. Hsp90 inhibitor BIIB028 blocks the binding of oncogenic client proteins to Hsp90, which may result in the proteasomal degradation of these proteins and so the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as Her2/Erbb2, Akt, Raf1, Bcr-Abl, and mutated p53, in addition to other molecules involved in cell cycle regulation and immune responses. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hsp90 inhibitor CNF2024  
An orally active, purine-scaffold, small-molecule inhibitor of heat shock protein 90 (HSP90) with potential antineoplastic activity. HSP90 inhibitor CNF2024 specifically blocks active HSP90, inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival; this may result in the inhibition of cellular proliferation in susceptible tumor cell populations. HSP90, a chaperone protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hsp90 inhibitor debio 0932  
An orally active and small molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor Debio 0932 specifically blocks Hsp90, thereby inhibiting its chaperone function and promoting the degradation of its client proteins, many of which are oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stabilization and degradation of many oncogenic signaling proteins. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HSP90 inhibitor HSP990  
An orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor Hsp990 binds to and inhibits the activity of Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90, upregulated in a variety of tumor cells, is a molecular chaperone that plays a key role in the conformational maturation, stability and function of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation and/or immune responses. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hsp90 inhibitor MPC-3100  
An orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor MPC-3100 selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival; this agent may inhibit the growth and survival of a wide variety of cancer cell types. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability, and degradation of many oncogenic signaling proteins. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HSP90 inhibitor PU-H71  
A purine-based heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Hsp90 inhibitor PU-H71 specifically inhibits active Hsp90, thereby inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may result in the inhibition of cellular proliferation in susceptible tumor cell populations. Hsp90, a molecular chaperone protein, is upregulated in a variety of tumor cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hsp90 inhibitor SNX-5422 mesylate  
The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5422 is rapidly converted to SNX-2112, which accumulates more readily in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hsp90 inhibitor XL888  
An orally bioavailable, ATP-competitive, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor XL888 specifically binds to Hsp90, inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival; inhibition of tumor cell proliferation may result. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins, including Her-2 and Met. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HspE7  
A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HSV-1 HF10  
A non-engineered, naturally oncolytic, replication-competent spontaneous herpes simplex virus (HSV) type I mutant variant. Upon intratumoral injection, HSV1 HF10 transfects, replicates in, and lyses rapidly dividing cells such as tumor cells. In addition, this agent may increase host immune responses that may kill non-infected tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HSV-TK-transduced donor lymphocytes  
A preparation of donor lymphocytes transduced with the "suicide" gene herpes simplex virus thymidine kinase (HSV-TK) with potential immunomodulating activity. Administration of HSV-TK-transduced lymphocytes after T cell-depleted allogeneic stem cell transplantation allows an early controllable immune reconstitution, which takes advantage of the antitumor effect of donor lymphocytes and helps to mitigate the risk of post-transplant opportunistic infection. To control graft-versus-host disease (GvHD) due to donor lymphocyte infusion, HSV-TK-transduced donor lymphocytes are selectively eliminated by administration of the antiviral agent ganciclovir. Ganciclovir, a prodrug, is readily phosphorylated by the suicide gene HSV-TK within HSV-TK-transduced lymphocytes to its monophosphate form and, subsequently, converted into its active triphosphate form, which specifically kills HSV-TK- transduced donor lymphocytes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hTERT I540/R572Y/D988Y multipeptide vaccine  
A peptide vaccine consisting of multiple epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with potential immunostimulating and antineoplastic activities. hTERT I540/R572Y/D988Y multipeptide vaccine contains strongly antigenic peptide epitopes I540 (9-mer), R572Y (9-mer) and D988Y (10-mer). Vaccination with this agent may elicit a cytotoxic T cell (CTL) response against telomerase-expressing tumor cells. Directly linked to tumorigenesis, telomerase is expressed in the majority of human cancer cells but is infrequently expressed in normal cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hTERT mRNA /survivin peptide-double-loaded autologous dendritic cell vaccine  
A cancer vaccine containing autologous dendritic cells (DCs) that are pulsed with mRNA encoding human telomerase reverse transcriptase (hTERT) and survivin peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT mRNA/survivin peptide-double-loaded autologous dendritic cell vaccine may elicit an immune response against cancer cells expressing hTERT and survivin by activating cytotoxic T-cells (CTLs), natural killer cells (NKs), and B-lymphocytes. The tumor associated antigens (TAAs) hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types and play key roles in tumor cell growth and survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hTERT vaccine V934/V935  
A cancer vaccine directed against human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with potential immunostimulating and antineoplastic activities. Upon administration, hTERT vaccine V934/V935 may elicit a cytotoxic T cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase is involved in the restoration and maintenance of telomere length and so the functional lifespan of cells. Abnormally reactivated in tumorigenesis, telomerase is expressed in the majority of human cancer cells but is not expressed or is expressed at very low levels in normal cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hTERT/survivin/CMV multipeptide vaccine  
A vaccine containing multiple peptides derived from the human telomerase reverse transcriptase (hTERT), survivin and cytomegalovirus (CMV), with potential immunostimulating and antineoplastic activities. Upon administration, hTERT/survivin/CMV multipeptide vaccine may elicit a cytotoxic T cell (CTL) response against tumor cells espressing hTERT, survivin and CMV. hTERT, the catalytic subunit of telomerase, and the inhibitor of apoptosis (IAP) family member survivin, both often upregulated in tumor cells, play key roles in tumor cell growth and survival. Further, CMV expression is correlated with certain types of cancer. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine  
A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hu14.18-IL2 fusion protein  
A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity. The monoclonal antibody portion of the hu14.18-IL2 fusion protein binds to tumor cells expressing the GD2 antigen (melanoma, neuroblastoma and certain other tumors); the Fc component of the fusion protein antibody moiety and natural killer (NK) cells mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cellular cytotoxicity (CDCC) towards GD2-expressing tumor cells. The localized IL2 moiety of the fusion protein stimulates NK and T-cell antitumor cellular immune responses. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

huachansu  
A traditional Chinese medicine (TCM) containing a water soluble Bufo toad skin extract that includes the cardiac glycosides bufalin, cinobufagin and resibufogenin with potential antineoplastic and antiangiogenic activities. Although the exact mechanism of action of this TCM has yet to be fully elucidated, huachansu, which may be administered in an injectable form, may induce cell cycle arrest and apoptosis by suppressing the expression of anti-apoptotic proteins, such as Bcl-2, while inducing the expression of pro-apoptotic proteins, such as BAX. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

huBC1-huIL12 fusion protein AS1409  
An immunoconjugate consisting of the anti-tumor cytokine interleukin-12 (IL-12) fused to the tumor-targeting antibody BC1 with potential immunostimulatory and antineoplastic activities. The antibody moiety of huBC1-huIL12 fusion protein AS1409 binds to the human fibronectin splice variant ED-B, delivering IL-12 directly to the tumor vasculature; tumor vasculature-targeted IL-12 initiates localized immune cascade responses and exhibits cytotoxic and anti-angiogenic activity while minimizing the systemic side effects of IL-12. The human fibronectin splice variant ED-B is over-expressed in the extracellular matrix and blood vessels of tumor tissues. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

human gp100 plasmid DNA vaccine  
A vaccine consisting of a plasmid DNA encoding the human melanoma-associated antigen gp100. Upon adminsistration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express this antigen, resulting in tumor cell lysis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

human lactoferrin peptide hLF1-11  
A synthetic peptide corresponding to the first 11 N-terminal amino acids of human lactoferrin (hLF1-11) with potential antimicrobial activity. Although the exact mechanism through which this peptide exerts its effect has yet to be fully elucidated, hLF1-11 binds ferric iron, limiting the availability of free iron for microbial functions. hLF1-11 may be effective against a variety of bacteria and fungi, including multidrug-resistant (MDR) strains of Acinetobacter baumannii and Staphylococcus aureus, and fluconazole-resistant Candida albicans strains. Human lactoferrin, a 692 amino acid glycoprotein belonging to the transferrin family of metal-binding proteins, can be found in human milk and other secretory fluids, and the secondary granules of polymorphonuclear (PMN) cells. Human lactoferrin plays a role in the innate defense of mucosal surfaces. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

human MHC non-restricted cytotoxic T-cell line TALL-104  
An allogeneic human cytotoxic T-lymphocyte cell line with potential antineoplastic activity. Human MHC non-restricted cytotoxic T-cell line TALL-104 is an IL-2-dependent human leukemic T cell line, expressing CD8 and CD3 but not CD16. Upon administration, human MHC non-restricted cytotoxic T-cell line TALL-104 interacts with tumor cells and activates apoptotic and necrotic pathways, resulting in tumor cell lysis. Endowed with MHC-non-restricted killer activity, these cells are cytotoxic against a broad range of tumor cells, sparing normal cells. In addition, TALL-104 may induce secretion of various cytokines, such as interferon-gamma, potentially enhancing its cytotoxic activity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

human monoclonal antibody 216  
A naturally-occurring human IgM monoclonal antibody with potential antineoplastic activity. Human monoclonal antibody 216, derived from the gene VH4-34, binds to the glycosylated epitope CDIM on the surface of both malignant and normal B cells. Upon binding to B cells, this antibody may crosslink two or more CDIM molecules, resulting in the formation of cell membrane pores, the disruption of cell membrane integrity, and B cell lysis; this mechanism of antibody-mediated cell death is direct and does not involve mechanisms of complement-mediated cytotoxicity or antibody-depndent cell-mediated cytotoxicity (ADCC). CDIM is the glyco-moiety of a 75 kD MW B-cell cell surface glycoprotein. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

human monoclonal antibody B11-hCG beta fusion protein CDX-1307  
A human monoclonal antibody (B11) directed against the mannose receptor and linked to the beta-subunit of human chorionic gonadotropin (hCG beta) with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of human monoclonal antibody B11-hCG beta fusion protein CDX-1307 binds to mannose receptors on antigen presenting cells (APCs), including human dendritic cells (DCs) and macrophages. Upon internalization and processing, APCs present the processed hCG beta antigen on their cell surfaces, which may initiate an antibody-dependent cell-mediated cytotoxicity (ADCC) response against hCG beta-expressing tumor cells. The tumor-associated antigen (TAA) hCG beta is selectively overexpressed by a number of tumors including breast, colorectal, pancreatic, bladder and ovarian tumors; its expression may correlate with the stage of disease. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

human myeloid progenitor cells CLT-008  
Early- to late-stage myeloid progenitor cells derived from adult human stem cells with potential hematopoietic activity. Upon infusion, human myeloid progenitor cells CLT-008 proliferate into mature myeloid cells, including granulocytes, macrophages, platelets, and erythrocytes. These myeloid progenitor cells die within forty-five days after a burst of hematopoiesis. This agent cannot create lymphoid cells, including T cells associated with graft-versus-host disease (GVHD). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

human papillomavirus 16 E7 peptide  
A synthetic peptide sequence of human papillomavirus (HPV) E7 nuclear protein which is used to produce vaccines against HPV infection and HPV-related neoplasms. HPV E7 oncogenic protein binds the retinoblastoma tumor suppressor protein, pRB, as well as a number of other cellular proteins, and serves as a transcriptional activator. This protein is important in the induction and maintenance of cellular transformation and is co-expressed in the majority of HPV-containing carcinomas. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine  
A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

human papillomavirus vaccine V503  
A vaccine consisting of noninfectious, recombinant virus-like particles (VLP) containing the major viral capsid protein L1 of nine strains of human papillomavirus (HPV), with potential immunoprotective activity. Vaccination with HPV V503 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against cells positive for any of these nine strains of HPV, thereby preventing cervical infection upon exposure to certain HPV subtypes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

human prostate-specific membrane antigen plasmid DNA vaccine  
A vaccine consisting of a plasmid DNA encoding the human prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express this antigen, resulting in tumor cell lysis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

human trefoil factor 1-secreting Lactococcus lactis AG013  
An oral rinse solution containing a strain of the bacteria Lactococcus lactis (L. lactis) genetically modified to express human Trefoil Factor 1 (hTFF1) with potential cytoprotective activity. With oral rinsing, human trefoil factor 1-secreting Lactococcus lactis AG013 may secrete and deliver hTFF1 to oral mucosal tissue, protecting or promoting the healing of damaged oral mucosa. hTFF1, a peptide belonging to the Trefoil factors family (TFF), is normally secreted by mucous epithelia and is involved in protecting mucosal tissue and maintaining mucosal surface integrity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

HuMax-CD38  
(Other name for: daratumumab)

Hyalo GYN  
(Other name for: hyaluronic acid-based hydrating vaginal gel)

hyaluronic acid  
A glucosaminoglycan consisting of D-glucuronic acid and N-acetyl-D-glucosamine disaccharide units that is a component of connective tissue, skin, vitreous humour, umbilical cord, synovial fluid and the capsule of certain microorganisms contributing to adhesion, elasticity, and viscosity of extracellular substances. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hyaluronic acid-based hydrating vaginal gel  
A clear, colorless water-based vaginal gel containing the partial benzyl ester of hyaluronic acid (HA) with potential hydrating activity. Upon vaginal application, HA adheres to the vaginal mucosa where it retains water, provides moisture to the vagina and protects the vaginal mucosa. This gel may provide relief in vaginal dryness and may prevent sexual discomfort, itching and irritation. This HA derivative is less susceptible to enzymatic breakdown and provides longer lasting activity compared to HA. HA is naturally present in the vaginal epithelium. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hycamtin  
(Other name for: topotecan hydrochloride)

Hycamtin Capsules  
(Other name for: oral topotecan hydrochloride)

hycanthone  
A thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. Hycanthone interferes with parasite nerve function, resulting in parasite paralysis and death. This agent also intercalates into DNA and inhibits RNA synthesis in vitro. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hydeltra  
(Other name for: prednisolone)

Hydeltrasol  
(Other name for: prednisolone)

hydrated sodium calcium aluminosilicate  
A naturally occurring, highly mineralized phyllosilicate clay used as a nutritional supplement with mycotoxin binding and protective activities. Upon ingestion prior to each meal, hydrated sodium calcium aluminosilicate is not absorbed by the gastrointestinal tract but rather binds certain food contaminants, including aflatoxin (AF) and fumonisin B1 (FB1), thereby reducing the bioavailability of these substances. Dietary exposure of AF and FB1 has been associated with an increased risk of certain cancers. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hydrazine sulfate  
The synthetic sulfate salt of hydrazine, a derivative of ammonia. Hydrazine inhibits the enzyme phosphoenol pyruvate carboxykinase, thereby blocking gluconeogenesis. This agent has been reported to decrease the excessive energy needs and cachexia of cancer patients. Classified as a likely human carcinogen, hydrazine sulfate is also a weak inhibitor of mono-amine oxidase (MAO). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hydrea  
(Other name for: hydroxyurea)

hydrocodone/acetaminophen  
A combination preparation of the analgesic acetaminophen and the semisynthetic opioid agonist hydrocodone with analgesic and antitussive activities. Acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis while hydrocodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hydrocortisone sodium succinate  
The sodium salt of hydrocortisone succinate with glucocorticoid property. Hydrocortisone sodium succinate is chemically similar to the endogenous hormone that stimulates anti-inflammatory and immunosuppressive activities, in addition to exhibiting minor mineralocorticoid effects. This agent binds to intracellular glucocorticoid receptors and is translocated into the nucleus, where it initiates the transcription of glucocorticoid-responsive genes, such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hydrocortone  
(Other name for: therapeutic hydrocortisone)

hydromorphone hydrochloride  
The hydrochloride salt of the semi-synthetic opioid hydromorphone with analgesic activity. Hydromorphone, the hydrogenated ketone of morphine, selectively binds the mu-opioid receptor, a G protein-coupled receptor. Binding stimulates the exchange of guanosine triphosphate (GTP) for guanosine diphosphate (GDP) on the G-protein complex, resulting in inhibition of plasma membrane-associated adenylate cyclase (AC) and a reduction in intracellular cyclic 3',5'-adenosine monophosphate (cAMP) levels. Due to a reduction in cAMP levels, voltage-gated potassium channels are activated, resulting in neuronal hyperpolarization and a reduction in neuronal excitability. In addition, this agent inhibits the opening of voltage-gated calcium channels, resulting in inhibition of calcium entry into neuronal cells and a reduction in the release of nociceptive neurotransmitters such as substance P and glutamate. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hydrostat  
(Other name for: hydromorphone hydrochloride)

hydroxychloroquine  
A 4-aminoquinoline with immunosuppressive, antiautophagy, and antimalarial activities. Although the precise mechanism of action is unknown, hydroxychloroquine may suppress immune function by interfering with the processing and presentation of antigens and the production of cytokines. As a lysosomotropic agent, hydroxychloroquine raises intralysosomal pH, impairing autophagic protein degradation; hydroxychloroquine-mediated accumulation of ineffective autophagosomes may result in cell death in tumor cells reliant on autophagy for survival. In addition, this agent is highly active against the erythrocytic forms of P. vivax and malariae and most strains of P. falciparum but not the gametocytes of P. falciparum. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hydroxyethyl starch  
A synthetic, nonionic hydroxyethyl derivative of starch used as a plasma expander when prepared in an isotonic solution. Upon intravenous administration, hydroxyethyl starch colloid increases blood volume and thus improves circulation. This agent is almost exclusively excreted by the kidneys and is potentially nephrotoxic. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hydroxyurea  
A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hymorphan  
(Other name for: hydromorphone hydrochloride)

Hyperacute Melanoma  
(Other name for: B16alphaGal melanoma vaccine)

HyperAcute-Lung Cancer Vaccine  
(Other name for: alpha-1,3-galactosyltransferase-expressing allogeneic lung tumor cell vaccine)

Hyperacute-Pancreatic Cancer Vaccine  
(Other name for: algenpantucel-L)

hyperbaric oxygen  
Oxygen that is administered at a higher pressure compared to standard (i.e. sea-level) atmospheric pressure. Administration of oxygen under hyperbaric conditions enhances the delivery of oxygen to hypoxic tumor cells, thereby increasing their sensitivity to radiation and chemotherapy. In addition, hyperbaric oxygen may improve the healing of radiation-induced injuries by improving oxygen delivery to damaged tissue. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hyperimmune bovine colostrum  
A dietary supplement consisting of bovine colostrum, containing high titers of immunoglobulins (Igs), with immunostimulating and anti-infective activities. Hyperimmune bovine colostrum is harvested during the first days after calving from cows that have been inoculated repeatedly with specific pathogens during pregnancy. In addition to high titers of anti-pathogen specific antibodies, hyperimmune colostrum is also rich in other immune factors, proline-rich polypeptides (PRP), lactoferrin, glycoproteins, lactalbumins, cytokines, growth factors, vitamins, and minerals. This dietary supplement may exhbit anti-infective activity in immunocompromised patients. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hypertonic saline  
Any solution of sodium chloride (NaCl) in water with a concentration of NaCl higher than that found in physiological saline (0.9% w/v). When administered in vivo, hypertonic saline (HTS) exhbits several physiological effects beneficial to cerebral injury including: 1) osmotic and vasoregulatory - by promoting the flow of excess water from cerebral tissue to the blood via osmosis and decreasing edema in the vascular endothelium of injured tissues, thus lowering vascular resistance and allowing more blood flow; 2) hemodymanic - by effectively expanding plasma volume; 3) immunomodulatory - by preventing leukocytes from becoming activated and adhering to injured neurons and; 4) neurochemical - by counteracting detrimental excitatory amino acids through the normalization of neuronal cell membranes and by restoration of normal electrolyte and neurotransmitter levels in brain cells, and normal cell volumes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hypoxia-activated prodrug PR610  
A proprietary, hypoxia-activated prodrug with potential antineoplastic activity. Upon administration, the hypoxia-activated prodrug PR610 is activated in the hypoxic cells within tumors into an irreversible pan-HER inhibitor via a mechanism of action not yet fully elucidated. As a result, this agent inhibits cellular proliferation and differentiation of tumor cells overexpressing HER kinases, which belong to the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. Healthy, normal tissues may be spared due to the hypoxia-specific activity of this agent, potentially reducing systemic toxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

hypoxia-activated prodrug TH-302  
A hypoxia-activated prodrug consisting of a 2-nitroimidazole phosphoramidate conjugate with potential antineoplastic activity. The 2-nitroimidazole moiety of hypoxia-activated prodrug TH-302 acts as a hypoxic trigger, releasing the DNA-alkylating dibromo isophosphoramide mustard moiety within hypoxic regions of tumors. Normoxic tissues may be spared due to the hypoxia-specific activity of this agent, potentially reducing systemic toxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Hytone  
(Other name for: therapeutic hydrocortisone)

Back to TopBack to Top